- Home
- CRAC vs NERV Comparison
CRAC vs NERV Comparison
Compare CRAC & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRAC | NERV |
|---|---|---|
| Founded | 2025 | 2007 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.3M | 189.1M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CRAC | NERV |
|---|---|---|
| Price | $9.97 | $4.32 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 81.2K | 74.6K |
| Earning Date | 01-01-0001 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $1.15 |
| 52 Week High | $10.00 | $12.46 |
Technical Indicators
Market Signals| Indicator | CRAC | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 59.32 | 53.98 |
| Support Level | $9.95 | $3.75 |
| Resistance Level | $10.00 | $4.65 |
| Average True Range (ATR) | 0.01 | 0.35 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 50.00 | 55.88 |
Price Performance
Historical ComparisonAbout CRAC Crown Reserve Acquisition Corp. I Class A Ordinary Shares
Crown Reserve Acquisition Corp I is a blank check company.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.